Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
Related Articles
Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC
Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.
Brain Metastases: Study Shows Cognitive Recovery After… : Oncology Times
An abstract is unavailable.
Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.
Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
MMS-I Treatment Is Linked to Low Recurrence, Mortality in Head and Neck Melanoma – Oncology Nurse Advisor
Investigators studied how Mohs micrographic surgery with melanocytic immunostains affected local recurrence and mortality rates in patients with invasive melanoma.
Cancer Patients Want Financial Toxicity Screening Early
Survey results suggest that cancer patients want financial toxicity screening to occur early, but screening preferences and practices vary.
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
A Promising Treatment for High-Risk Non-Muscle Invasive… : Oncology Times
An abstract is unavailable.